"Diabetes Day" market: more than 100 million patients, more than 10 billion retail sales, top 10 brand foreign investment accounted for 7 seats

Today, we usher in the 11th "United Nations Diabetes Day" Diabetes is a common endocrine and metabolic disease Its basic pathological characteristics are a series of metabolic disorders such as glucose, protein and fat caused by insufficiently secreting insulin or the peripheral tissue is not sensitive to insulin According to the data of the International Diabetes Federation (IDF), in 2015, there were 415 million people suffering from diabetes in the world China is the country with the largest number of people suffering from diabetes in the world The number of patients is about 110 million, accounting for 10% of the total adult population! With the advent of "United Nations Diabetes Day", new Kangjie specially collated and released the data of diabetes drug market of national retail pharmacies, hoping to provide some market dimension references for the health industry and the public to understand the situation of diabetes disease and treatment 1 The scale of diabetes drug market continues to expand, the prevalence of diabetes in China is increasing year by year, which is the result of the interaction of many factors, such as genetic factors, the improvement of living standards, sedentary and lack of exercise, and the aging of population With the increase of the number of patients and the enhancement of self-care awareness, the demand of diabetes drug market has expanded In recent years, the diabetes drug market in China has been steadily increasing In 2016, the total market size of diabetes drugs reached 47.5 billion yuan Hospitals at city level and county level are still the main market for diabetes drugs, accounting for 62% of the total, and retail pharmacies for 24% In 2016, the total market size of diabetes drugs reached 47.5 billion yuan, an increase of 15.4% year on year The market scale of retail drugstores reached 11.3 billion yuan, an increase of 11.7% over 2015 The growth rate is slightly lower than that of the overall market of 15.4% Thanks to the comprehensive promotion of hierarchical diagnosis and treatment, the market share of primary hospitals has increased to 14% The share of retail pharmacies is 24% With the gradual implementation of policies such as medical insurance and fee control, as well as the promotion of policies such as medicine separation and prescription outflow, the share of hospital channels will decline year by year In 2017, the market share of diabetes in retail pharmacies will keep growing, which is expected to be higher than the overall market 2 Types and proportion of diabetic drugs: oral hypoglycemic drugs, insulin and its analogues and other non insulin hypoglycemic drugs Type 2 diabetes is the most common type of disease, accounting for about 90% Compared with type 1 diabetes, which needs continuous insulin supply, type 2 patients mainly control their blood glucose by oral hypoglycemic drugs In 2016, the market scale of oral hypoglycemic drugs in retail pharmacies was 7.24 billion yuan, up 13% year on year According to the CMH monitoring data of Zhongkang, chemical drugs play a leading role in oral hypoglycemic drugs, accounting for 89.9% of the total, while proprietary Chinese drugs account for 9.3% From the sub categories of oral hypoglycemic drugs, in 2016, α - glucosidase inhibitors accounted for the largest market share, reaching 25.6%, followed by sulfonylureas 23.2% and biguanides 20.8% α - glucosidase inhibitors can reduce postprandial blood glucose by delaying the decomposition of sucrose, starch and maltose into glucose in the small intestine The main varieties are acarbose, voglibose and miglitol Acarbose has been playing a leading role in oral hypoglycemic drugs in retail pharmacies for many years CMH monitoring data shows that in 2016, α - glucosidase inhibitors reached 1.9 billion yuan in the retail drugstore market, of which acarbose accounted for 90%, while voglibose only accounted for 7% Bayer is the leading manufacturer in acarbose market, followed by Huadong Pharmaceutical (caboping) and LVYE Baoguang (Beixi) Sulfonylureas can increase the insulin level in vivo by stimulating the insulin secretion of β cells of islets of Langerhans, and play a role in lowering blood glucose Sulfonylureas are the second subclass of oral antidiabetic drugs In 2016, the market scale of sulfonylureas in retail drugstores was 1.68 billion yuan There are many varieties in this sub category In 2016, the varieties with annual sales of more than 100 million in retail pharmacies included gliclazide, glimepiride, glipizide and Gliquidone, accounting for 99% of the total Glimepiride is the third generation of sulfonylurea long-acting antidiabetic drug, which has been improved in safety and effectiveness, and its market share is rising rapidly Biguanides are the first choice of hypoglycemic drugs for children, overweight and obese patients with type 2 diabetes Besides lowering blood sugar, they also have cardiovascular protection The main variety is metformin In 2016, the sales volume of metformin varieties in retail drugstores was 1.5 billion yuan, up 13% year on year There are many manufacturers of this product In 2016, the total share of top 5 manufacturers reached 62%, with a high concentration of manufacturers Among them, the manufacturer with the largest share is Shiguibao, over 40%, followed by Guizhou Tian'an and Hengrui DPP-4 inhibitor the growth rate of DPP-4 inhibitor reached 39% in 2016, which is a fast growing category In 2016, the market scale of retail drugstores reached 300 million yuan At present, the five DPP-4 inhibitors listed in China are exclusive varieties, including siggliptin and saggliptin, which have been included in the 2017 version of the medical insurance catalogue for the treatment of type 2 diabetes It is expected that the category will grow significantly after entering the medical insurance In 2016, the market share of DPP-4 inhibitors in retail pharmacies accounted for 64%, and the market share of its compound preparation, jienoda (cigliptin metformin), kept expanding year by year after its launch 3 Top 10 of the best-selling varieties of oral hypoglycemic drugs in the competition pattern according to the monitoring data of Zhongkang CMH, the share of top 10 of the best-selling varieties of oral hypoglycemic drugs in retail pharmacies in 2016 was 88.4%, with a high market concentration The top 10 varieties are all single prescription preparations, and the relatively more efficient and convenient compound preparations have a huge development space in retail pharmacies Market share: Top 10 manufacturers take oral hypoglycemic drugs in retail drugstores, with domestic and foreign enterprises accounting for half of the market In 2016, foreign-funded enterprises were slightly better, accounting for 51% of the share, while domestic enterprises accounted for 49% However, the reason why domestic enterprises have such a market performance is due to the large number of manufacturers, the share of each manufacturer is relatively small, while that of foreign enterprises is the opposite In the top 10 manufacturers' share ranking, the performance of domestic enterprises is slightly behind that of foreign enterprises In 2016, the top 10 manufacturers of oral hypoglycemic drugs in retail pharmacies accounted for 65.7%, with high market concentration Among them, there are 6 foreign-funded enterprises with a total share of 47.5%, and 4 domestic enterprises with a total share of 18.2% Market share of top 10 brand performance in 2016, the share of top 10 brand of oral hypoglycemic drugs in retail pharmacies accounted for 59%, among which, there are 7 foreign brands, with a total share of 46%, occupying a comparative advantage position; domestic brands are relatively weak, with only 3 brands, with a total share of 13% The most outstanding brand is Bayer's Baitangping, which has been ranked first in oral antidiabetic drugs for many consecutive years, followed by Bristol Myers Squibb's gehuazhi and novo Nord's novo Helong; Baiyunshan's Xiaoke pill is the only Chinese patent medicine in top 10, and also the largest domestic antidiabetic drug in retail drugstores In addition, the domestic antidiabetic drug brands and Huadong pharmaceutical's Kabopin, Fulaidi, Tian'an, Guizhou.